For decades, virologists knew that enteroviruses pulled a kind of bait-and-switch inside human cells, repurposing the cell’s own molecular machinery to copy viral genetic material instead of simply reading it. What they couldn’t see was exactly how the trick worked at the atomic level. Now, a team of structural biologists has captured that moment in extraordinary detail, revealing how a small, clover-shaped piece of RNA at the tip of the viral genome locks onto a viral protein called 3C to flip the switch from translation to replication.
The findings, published in Nature Communications in May 2026, include two crystal structures resolved at 2.69 and 2.41 angstroms, sharp enough to map individual atomic contacts between the RNA and the protein. Because this mechanism is shared across the enterovirus genus, the same molecular handshake appears in the pathogens responsible for paralytic polio, coxsackievirus-driven myocarditis, EV-D68 respiratory illness, and a significant share of common colds.
That breadth is what makes the discovery especially striking. Enteroviruses collectively cause an estimated 10 to 15 million symptomatic infections each year in the United States, according to longstanding CDC estimates. Yet no approved antiviral drug targets the group broadly. The new structures offer medicinal chemists, for the first time, a precise atomic blueprint of a single choke point shared across more than 100 enterovirus serotypes.
The cloverleaf: a tiny RNA structure with an outsized role
Every enterovirus genome begins with an untranslated region that never gets turned into protein. Nestled at the very start of that region is a compact RNA structure called the 5-prime cloverleaf, named for the way its stems and loops fold into a shape resembling a four-leaf clover. Despite its small size, this element acts as a molecular command center. Early in infection, it helps recruit the cell’s own ribosomes to begin translating viral proteins. Later, it orchestrates the switch to genome replication by recruiting viral protein 3C (or its precursor, 3CD) along with a host protein called PCBP2.
The idea that the cloverleaf serves as a landing pad for both viral and host proteins was established by earlier biochemical work on poliovirus. A 2006 study demonstrated that PCBP2, the poliovirus cloverleaf RNA, and the viral 3CD protein form a ternary complex required for negative-strand RNA synthesis. Mutations that disrupted PCBP2 binding crippled viral replication, proving the complex was not a bystander but a functional necessity.
What was missing until now was a high-resolution picture of the cloverleaf actually gripping the viral protein. A separate structural study had previously solved the cloverleaf in its free, unbound state, mapping its subdomain architecture and junction geometry. The new work captures the bound conformation, and the differences between the two states are where potential drug targets emerge. A small molecule that locks the cloverleaf into its unbound shape could, in principle, prevent 3C from ever docking.
Why one target could matter for many diseases
Enteroviruses are a genus of staggering diversity. They include poliovirus, the coxsackieviruses linked to viral heart inflammation, EV-D68 (associated with acute flaccid myelitis in children), rhinoviruses responsible for many common colds, and dozens of other serotypes that cause hand-foot-and-mouth disease, viral meningitis, and neonatal sepsis. Despite that variety, the 5-prime cloverleaf and its interaction with 3C are conserved features, maintained by evolution because the virus cannot replicate without them.
A detailed life-cycle review published in Nature Reviews Microbiology catalogues the stages of enterovirus infection, from cell entry through uncoating, translation, replication-organelle formation, assembly, and release. It identifies the 5-prime untranslated region and its internal ribosome entry site (IRES) as two of several druggable nodes. The cloverleaf sits within that same untranslated region, reinforcing its status as a high-value intervention point.
The logic is straightforward: if a single drug could jam this conserved switch, it might limit replication across many enterovirus species simultaneously. That would represent a fundamentally different approach from the serotype-specific vaccines that have worked for poliovirus but have never been scaled to the rest of the genus. No existing antiviral drug targets enteroviruses broadly, which is one reason most enteroviral infections are still treated with supportive care alone.
What the structures cannot yet tell us
Crystal structures are among the most reliable forms of biological evidence. The resolution figures reported here are not estimates or computational models; they represent direct experimental measurements of electron density. When researchers say a viral protein contacts a specific RNA nucleotide at 2.41 angstroms, the claim carries high confidence.
But atomic pictures of molecules in a crystal are not the same as proof that a drug will work in a patient. Several important gaps remain.
No patient-level outcome data connect the 3C-cloverleaf interaction to clinical severity in myocarditis, acute flaccid myelitis, or any other enteroviral disease. The structural work explains how the virus toggles its genome from being read to being copied, but whether blocking that step in a living person would reduce heart damage or paralysis risk has not been tested. Animal and cell-culture experiments are the logical next step, and none have been reported from this research group so far.
Strain-specific variation adds complexity. The new structures cover representative enteroviruses, but the genus contains more than 100 serotypes. Whether the junction flexibility of the cloverleaf varies enough between, say, EV-D68 and coxsackievirus B3 to change how tightly a candidate drug would need to bind is an open question. The structural data hint at measurable differences in loop geometry, but quantitative binding kinetics for a hypothetical inhibitor remain speculative without dedicated medicinal-chemistry follow-up.
There are also unanswered questions about host factors beyond PCBP2. The cloverleaf sits upstream of the IRES that recruits host translation factors, and subtle changes in RNA folding could alter the balance between translation and replication in ways that static crystal snapshots cannot capture. Without time-resolved structural data from inside infected cells, scientists are still inferring these dynamics from frozen images and test-tube assays.
From atomic blueprint to antiviral: what comes next
For medicinal chemists, the immediate value of these structures is a precise template. The bound conformation of the cloverleaf reveals pockets and grooves where a small molecule might wedge in to block 3C docking. The comparison with the unbound conformation highlights which parts of the RNA move during protein recognition, offering clues about where a molecular “doorstop” could be most effective.
But the path from a beautiful structure to a working therapy is long and uncertain. Candidate molecules would need to bind tightly enough to outcompete the viral protein, remain stable in the body, avoid toxicity, and work across enough serotypes to justify broad-spectrum claims. Each of those hurdles has stalled promising antiviral programs in the past.
What the new work does accomplish is a shift in the conversation. For years, the enterovirus field has lacked a unifying drug target with atomic-level structural data to guide design. That gap has now been filled. Whether the research community and pharmaceutical industry move quickly enough to exploit it will depend on funding, collaboration, and the unpredictable timing of the next enterovirus outbreak that reminds the public these pathogens never really went away.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
